+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii



A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii



Infectious Diseases and Therapy 3(2): 69-81



As antibiotic resistance continues to increase among Gram-negative organisms such as Acinetobacter baumannii there is a growing need for novel therapies to overcome these resistance mechanisms. Antibiotics active against multidrug-resistant A. baumannii (MDRAB) are few, and agents in development are primarily active against other multidrug-resistant Gram-negative organisms. The combinations of colistin and antimicrobials such as glycopeptides and lipopeptides are unique potential treatment modalities against MDRAB. For both lipopeptides and glycopeptides in vitro data have demonstrated significant synergy, resulting in rapid bactericidal activity in time-kill curves. Several invertebrate in vivo models have also demonstrated increased survival compared to colistin alone. Currently, very little clinical data have focused on using these combinations for infections caused exclusively by multidrug-resistant Gram-negatives. The combination of vancomycin and colistin has been studied with conflicting results regarding both improved outcomes and risk of nephrotoxicity. Although in vitro and in vivo models have proved promising, further investigation is required to provide clinical data necessary to support the use of these combinations. The objective of this review is to summarize literature currently available for the novel combination of lipopeptides or glycopeptides with colistin for the treatment of A. baumannii, in particular MDRAB.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 057042620

Download citation: RISBibTeXText

PMID: 25475412

DOI: 10.1007/s40121-014-0051-9


Related references

In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii. Gms Hygiene and Infection Control 9(2): Doc14, 2014

In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii. Annals of Laboratory Medicine 36(2): 124-130, 2016

Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection 42(1): 37-42, 2014

Intraventricular and intrathecal colistin as the last therapeutic resort for the treatment of multidrug-resistant and extensively drug-resistant Acinetobacter baumannii ventriculitis and meningitis: a literature review. International Journal of Antimicrobial Agents 41(6): 499-508, 2013

Antimicrobial effects of varied combinations of meropenem, sulbactam, and colistin on a multidrug-resistant Acinetobacter baumannii isolate that caused meningitis and bacteremia. Microbial Drug Resistance 14(3): 233-237, 2008

Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. Journal of Antimicrobial ChemoTherapy 61(2): 417-420, 2008

Synergy of imipenem/colistin methanesulfonate combinations against imipenem-nonsusceptible multidrug-resistant Acinetobacter baumannii. Journal of Microbiology Immunology and Infection 47(5): 406-411, 2014

Multidrug-resistant Acinetobacter baumannii ventriculitis: successful treatment with intraventricular colistin. Acta Neurochirurgica 151(11): 1465-1472, 2009

Rifampicin as adjunct to colistin therapy in the treatment of multidrug-resistant Acinetobacter baumannii. Annals of PharmacoTherapy 48(6): 766-771, 2014

Treatment of nosocomial meningitis due to a multidrug resistant Acinetobacter baumannii with intraventricular colistin. Saudi Medical Journal 26(4): 656-658, 2005

Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clinical Infectious Diseases 45(5): 594-598, 2007

Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intravenous and intraventricular colistin. Annals of Tropical Paediatrics 29(2): 141-147, 2009

Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clinical Infectious Diseases 41(5): 754-757, 2005

Successful treatment of multidrug-resistant Acinetobacter baumannii ventriculitis with intrathecal and intravenous colistin. Minerva Anestesiologica 76(11): 957-960, 2010

Aerosolized colistin in the treatment of multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa pneunomia. Medicina Clinica 129(10): 397, 2007